Frutinib
Generic: Fruquintinib
Daily Dose:
Duration:
Cheaper & Alternative Brands
Same generic (Fruquintinib), same form (Capsule)No other brands currently registered with this exact active generic and dosage form.
Clinical Prescribing Information
Medical monograph and safety information for healthcare professionals & patients.Indications & Clinical Uses
Frutinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild type and medically appropriate, an anti-EGFR therapy.
Dosage & Administration
The recommended dose of Fruquintinib is 5 mg orally once daily for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity. Take Fruquintinib with or without food at approximately the same time each day. Swallow the Fruquintinib capsule whole. Take a missed dose if less than 12 hours have passed since the missed scheduled dose. Do not take two doses on the same day to make up for a missed dose. Do not take an additional dose if vomiting occurs after taking Fruquintinib but continue with the next scheduled dose.
Dose Modification
: Recommended Dose Reductions for Fruquintinib. First dose reduction 4 mg orally once daily. Second dose reduction 3 mg orally once daily. Permanently discontinue Fruquintinib in patients unable to tolerate 3 mg orally once daily.
Side Effects & Adverse Reactions
The following clinically significant adverse reactions are described elsewhere in the labeling:
Hypertension
Hemorrhagic Events
Infections
Gastrointestinal Perforation
Hepatotoxicity
Proteinuria
Palmar-Plantar Erythrodysesthesia (PPE)
Posterior Reversible Encephalopathy Syndrome (PRES)
Warnings & Precautions
Hypertension
: Frutinib can cause hypertension. Do not initiate Frutinib unless blood pressure is adequately controlled. Monitor blood pressure weekly the first month, at least monthly thereafter.
Hemorrhagic Events
: Frutinib can cause serious hemorrhagic events, which may be fatal. Permanently discontinue Frutinib in patients with severe or life-threatening hemorrhage.
Infections
: Frutinib can cause an increased risk of infections, including fatal infections.
Pharmacology & Mechanism of Action
Fruquintinib is a small molecule kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3 with IC50 values of 33, 35, and 0.5 nM, respectively. In vitro studies showed fruquintinib inhibited VEGF-mediated endothelial cell proliferation and tubular formation. In vitro and in vivo studies showed fruquintinib inhibited VEGF-induced VEGFR-2 phosphorylation. In vivo studies showed fruquintinib inhibited tumor growth in a tumor xenograft mouse model of colon cancer.